Renaissance Technologies
ALXO icon

Renaissance Technologies’s ALX Oncology ALXO Stock Holding History

Renaissance Technologies’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
732,599
+309,500
+73% +$590K ﹤0.01% 2061
2025
Q4 		$478K Buy
423,099
+258,600
+157% +$392K ﹤0.01% 2590
2025
Q3 		$301K Buy
164,499
+79,100
+93% +$68.5K ﹤0.01% 2993
2025
Q2 		$35.4K Buy
85,399
+71,100
+497% +$35.9K ﹤0.01% 3427
2025
Q1 		$8.91K Buy
+14,299
New +$17.2K ﹤0.01% 3394
2024
Q4 		– Sell
-155,300
Closed -$283K – 3547
2024
Q3 		$283K Sell
155,300
-282,900
-65% -$1.05M ﹤0.01% 3002
2024
Q2 		$2.64M Buy
438,200
+204,100
+87% +$2.51M ﹤0.01% 1699
2024
Q1 		$2.61M Sell
234,100
-36,400
-13% -$511K ﹤0.01% 1846
2023
Q4 		$4.03M Buy
270,500
+58,000
+27% +$550K 0.01% 1487
2023
Q3 		$1.02M Buy
212,500
+29,700
+16% +$161K ﹤0.01% 2277
2023
Q2 		$1.37M Buy
182,800
+55,981
+44% +$366K ﹤0.01% 2247
2023
Q1 		$573K Buy
126,819
+31,019
+32% +$235K ﹤0.01% 2809
2022
Q4 		$1.08M Sell
95,800
-74,800
-44% -$840K ﹤0.01% 2486
2022
Q3 		$1.63M Sell
170,600
-57,083
-25% -$665K ﹤0.01% 2160
2022
Q2 		$1.84M Buy
227,683
+78,883
+53% +$859K ﹤0.01% 2244
2022
Q1 		$2.52M Sell
148,800
-19,100
-11% -$326K ﹤0.01% 2059
2021
Q4 		$3.61M Buy
+167,900
New +$7.24M ﹤0.01% 1733

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Renaissance Technologies's ALXO Position: Q1 2026 in Review

Renaissance Technologies increased its ALX Oncology (ALXO) stake by 73% in Q1 2026, buying an estimated $590K and bringing the position to 732,599 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2061.

Renaissance Technologies first reported a position in ALXO in Q4 2021 and has held it in 17 quarters since. The position peaked at $4.03M in Q4 2023. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Renaissance Technologies held 732,599 shares of ALX Oncology worth $1.47M as of Q1 2026.
  • Renaissance Technologies bought 309,500 ALX Oncology shares in Q1 2026, an estimated $590K.
  • ALX Oncology made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2061 holding.
  • Renaissance Technologies first reported a position in ALX Oncology in Q4 2021 and has held it in 17 quarters since.
  • Renaissance Technologies's ALX Oncology position peaked at $4.03M in Q4 2023.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.